BEIJING and BRIDGEWATER, N.J., Dec. 6, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the company's compound, GZR18, to
Currently, there are 537 million adults (20-79 years) living with diabetes worldwide2, while type 2 diabetes mellitus accounts for approximately 90% of all diabetes cases.3 Gan & Lee understands the global burden of type 2 diabetes mellitus. "The FDA's clearance of the IND application for GZR18, is a significant milestone for our company as we strive to globally provide additional treatment options to patients with type 2 diabetes," said Kaushik Dave RPh., PhD, MBA, Vice President, Global Regulatory Affairs. This IND acceptance by the FDA will allow Gan & Lee to proceed with GZR18 Phase 1 clinical trial.
About Gan & LeeGan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®).